Annals of Nuclear Medicine

, Volume 27, Issue 10, pp 880–885 | Cite as

Limitation of 2-deoxy-2-[F-18]fluoro-d-glucose positron emission tomography (FDG-PET) to detect early synchronous primary cancers in patients with untreated head and neck squamous cell cancer

  • Atsushi Hanamoto
  • Yukinori TakenakaEmail author
  • Eku Shimosegawa
  • Yoshifumi Ymamamoto
  • Tadashi Yoshii
  • Susumu Nakahara
  • Jun Hatazawa
  • Hidenori Inohara
Original Article



Patients with head and neck squamous cell carcinoma (HNSCC) often develop synchronous multiple primary cancers. It is important to detect second primary cancer in HNSCC patients, because it influences treatment selection of primary cancer. The aim of this study was to evaluate the utility of 2-deoxy-2-[F-18]fluoro-d-glucose (FDG)-positron emission tomography (PET) for detecting synchronous primary cancers at the initial staging of patients with HNSCC.


Three hundred and forty-seven patients with untreated HNSCC underwent FDG-PET with or without computed tomography fusion and other routine workups, including upper gastrointestinal Lugol chromoendoscopy, for the initial staging. We examined the prevalence of second primary cancer in these patients and the utility of PET.


We identified 57 synchronous primary cancers in 53 patients, of which only 33 % were detected with PET. The most common site for the second primary cancer was the esophagus (49 %), followed by stomach (14 %) and head and neck (11 %). Most early-stage esophageal cancers and stomach cancers were detected using Lugol chromoendoscopy but not PET.


Although PET is useful for detecting synchronous primary cancers, it is not a sensitive technique for detecting early esophageal cancers and gastric cancers. Therefore, Lugol chromoendoscopy is indispensable for detecting synchronous upper gastrointestinal cancers in HNSCC patients.


FDG-PET Head and neck cancer Second primary cancer Chromoendoscopy Synchronous esophageal cancer Synchronous gastric cancer 


  1. 1.
    Leon X, Quer M, Diez S, Orus C, Lopez-Pousa A, Burgues J. Second neoplasm in patients with head and neck cancer. Head Neck. 1999;21:204–10.PubMedCrossRefGoogle Scholar
  2. 2.
    Jones AS, Morar P, Phillips DE, Field JK, Husband D, Helliwell TR. Second primary tumors in patients with head and neck squamous cell carcinoma. Cancer. 1995;75:1343–53.PubMedCrossRefGoogle Scholar
  3. 3.
    Hsairi M, Luce D, Point D, Rodriguez J, Brugere J, Leclerc A. Risk factors for simultaneous carcinoma of the head and neck. Head Neck. 1989;11:426–30.PubMedCrossRefGoogle Scholar
  4. 4.
    Gluckman JL, Crissman JD. Survival rates in 548 patients with multiple neoplasms of the upper aerodigestive tract. Laryngoscope. 1983;93:71–4.PubMedGoogle Scholar
  5. 5.
    Raghavan U, Quraishi S, Bradly PJ. Multiple primary tumors in patients diagnosed with hypopharyngeal cancer. Otolaryngol Head Neck Surg. 2003;128:419–25.PubMedCrossRefGoogle Scholar
  6. 6.
    Sobin LH, Gospodarowicz MK, Wittekind C. TNM classification of malignant tumours. 7th ed. Hoboken: Wiley-Blackwell; 2009.Google Scholar
  7. 7.
    Warren S, Gates O. Multiple malignant tumors: a survey of literature and statistical study. Am J Cancer. 1932;51:1358–414.Google Scholar
  8. 8.
    Fleming AJ Jr, Smith SP Jr, Paul CM, Hall NC, Daly BT, Agrawal A, et al. Impact of [18F]-2-fluorodeoxyglucose-positron emission tomography/computed tomography on previously untreated head and neck cancer patients. Laryngoscope. 2007;117:1173–9.PubMedCrossRefGoogle Scholar
  9. 9.
    Gordin A, Golz A, Keidar Z, Daitzchman M, Bar-Shalom R, Israel O. The role of FDG-PET/CT imaging in head and neck malignant conditions: impact on diagnostic accuracy and patient care. Otolaryngol Head Neck Surg. 2007;137:130–7.PubMedCrossRefGoogle Scholar
  10. 10.
    Keyes JW Jr, Watson NE Jr, Williams DW 3rd, Greven KM, McGuirt WF. FDG PET in head and neck cancer. AJR Am J Roentgenol. 1997;169(6):1663–9.PubMedCrossRefGoogle Scholar
  11. 11.
    Zanation AM, Sutton DK, Couch ME, Weissler MC, Shokley WW, Shores CG. Use, accuracy and implications for patient management of [18F]-2-Fluorodeoxyglucose-positron emission/computerized tomography for head and neck tumors. Laryngoscope. 2005;115:1186–90.PubMedCrossRefGoogle Scholar
  12. 12.
    Hannah A, Scott AM, Tochon-Danguy H, Chan JG, Akhurst T, Berlangieri S. Evaluation of 18 F-fluorodeoxyglucose positron emission tomography and computed tomography with histopathologic correlation in the initial staging of head and neck cancer. Ann Surg. 2002;236:208–17.PubMedCentralPubMedCrossRefGoogle Scholar
  13. 13.
    Quon A, Fischbein NJ, McDougall IR, Le QT, Loo BW Jr, Pinto H. Clinical role of 18-FDG PET/CT in the management of squamous cell carcinoma of the head and neck and thyroid carcinoma. J Nucl Med. 2007;48:58S–67S.PubMedGoogle Scholar
  14. 14.
    Inohara H, Enomoto K, Tomiyama Y, Higuchi I, Inoue T, Hatazawa J. Impact of FDG-PET on prediction of clinical outcome after concurrent chemoradiotherapy in hypopharyngeal carcinoma. Mol Imaging Biol. 2010;12:89–97.PubMedCrossRefGoogle Scholar
  15. 15.
    Connell CA, Corry J, Milner AD, Hogg A, Hicks RJ, Rischin D, et al. Clinical impact of, and prognostic stratification by, F-18 FDG PET/CT in head and neck mucosal squamous cell carcinoma. Head Neck. 2007;29:986–95.PubMedCrossRefGoogle Scholar
  16. 16.
    Haerle SK, Strobel K, Hany TF, Sidler D, Stoeckli SJ. (18) F-FDG-PET/CT versus panendoscopy for the detection of synchronous second primary tumors in patients with head and neck squamous cell carcinoma. Head Neck. 2010;32:319–25.PubMedGoogle Scholar
  17. 17.
    Suzuki H, Hasegawa Y, Terada A, Ogawa T, Hyodo I, Suzuki M, et al. Limitations of FDG-PET and FDG-PET with computed tomography for detecting synchronous cancer in pharyngeal cancer. Arch Otolaryngol Head Neck Surg. 2008;134:1191–5.PubMedCrossRefGoogle Scholar
  18. 18.
    Strobel K, Haerle SK, Stoeckli SJ, Schrank M, Soyka JD, Veit-Haibach P, et al. Head and neck squamous cell carcinoma (HNSCC)—detection of synchronous primaries with (18) F-FDG-PET/CT. Eur J Nucl Med Mol Imaging. 2009;36:919–27.PubMedCrossRefGoogle Scholar
  19. 19.
    Kato H, Kuwano H, Nakajima M, Miyazaki T, Yoshikawa M, Masuda N, et al. Comparison between positron emission tomography and computed tomography in the use of the assessment of esophageal carcinoma. Cancer. 2002;94:921–8.PubMedCrossRefGoogle Scholar
  20. 20.
    Himeno S, Yasuda S, Shimada H, Tajima T, Makuuchi H. Evaluation of esophageal cancer by positron emission tomography. Jpn J Clin Oncol. 2002;32:340–6.PubMedCrossRefGoogle Scholar
  21. 21.
    Yamada A, Oguchi K, Fukushima M, Imai Y, Kadoya M. Evaluation of 2-deoxy-2-[18F]fluoro-d-glucose positron emission tomography in gastric carcinoma: relation to histological subtypes, depth of tumor invasion, and glucose transporter-1 expression. Ann Nucl Med. 2006;20:597–604.PubMedCrossRefGoogle Scholar
  22. 22.
    Lim JS, Yun MJ, Kim MJ, Hyung WJ, Park MS, Choi JY, et al. CT and PET in stomach cancer: preoperative staging and monitoring of response to therapy. Radiographics. 2006;26:143–56.PubMedCrossRefGoogle Scholar
  23. 23.
    Yabuki K, Kubota A, Horiuchi C, Taguchi T, Nishimura G, Inamori M. Limitations of PET and PET/CT in detecting upper gastrointestinal synchronous cancer in patients with head and neck carcinoma. Eur Arch Otorhinolaryngol. 2013;270:727–33.PubMedCrossRefGoogle Scholar
  24. 24.
    Muto M, Minashi K, Yano T, Saito Y, Oda I, Nonaka S, et al. Early detection of superficial squamous cell carcinoma in the head and neck region and esophagus by narrow band imaging: a multicenter randomized controlled trial. J Clin Oncol. 2010;28:1566–72.PubMedCentralPubMedCrossRefGoogle Scholar

Copyright information

© The Japanese Society of Nuclear Medicine 2013

Authors and Affiliations

  • Atsushi Hanamoto
    • 1
  • Yukinori Takenaka
    • 1
    Email author
  • Eku Shimosegawa
    • 2
  • Yoshifumi Ymamamoto
    • 1
  • Tadashi Yoshii
    • 1
  • Susumu Nakahara
    • 1
  • Jun Hatazawa
    • 2
  • Hidenori Inohara
    • 1
  1. 1.Department of Otorhinolaryngology-Head and Neck SurgeryOsaka University Graduate School of MedicineSuitaJapan
  2. 2.Department of Nuclear Medicine and Tracer KineticsOsaka University Graduate School of MedicineSuitaJapan

Personalised recommendations